FDA Approves Lisraya (Brepocitinib) as First Oral Therapy for Rare Dermatomyositis, Marking a Milestone for Priovant Therapeutics
The U.S. Food and Drug Administration (FDA) has granted approval for brepocitinib, marketed as Lisraya,...
Knowledge and News for the Global Fight Against Cancer.
The U.S. Food and Drug Administration (FDA) has granted approval for brepocitinib, marketed as Lisraya,...
The biotechnology sector is experiencing an unprecedented resurgence in August 2026, marked by the benchmark...
Two years ago, Alnylam Pharmaceuticals unveiled groundbreaking study data, demonstrating that patients suffering from a...
The biopharmaceutical sector witnessed a flurry of significant developments this past week, marked by crucial...
As the global community observes World Cancer Support Month, attention is critically drawn not only...
The pharmaceutical landscape for metastatic pancreatic cancer has been fundamentally reshaped with the immediate launch...
AstraZeneca and Amgen have announced a significant clinical triumph for their co-developed biologic, Tezspire (tezepelumab),...
Outer Bio, a pioneering startup operating at the nexus of biotechnology and artificial intelligence, has...
For decades, researchers have pursued an ambitious idea: What if a vaccine could teach a...
The biopharmaceutical sector is witnessing a flurry of significant developments, from pioneering real-world data demonstrating...